Because Patients Matter
Make Better-Informed Decisions
Be Ready Against Hereditary Cancer
Helping Children Lead Better Lives
CENTOGENE’s Medical Genetic Liaison Kriti Menon will provide an overview of WGS, literature-based evidence, its advantages & limitations, and the relevance of research variants & data re-evaluation. At the end of the webinar, she will share different clinical cases studies and lessons learned.
Until now, a common industry approach for testing HLA-A 31:01 (tag SNP rs1061235) has produced a high false positive rate of approximately 40%. Without separate verification, this could have the clinical outcome of inappropriately excluding the use of a valuable drug, carbamazepine which is associated with a 5-fold increased incidence in hypersensitivity reactions in the presence of this allele.
Mark your calendars for 13 January (Wednesday) for our next case study webinar, ‘The Role of CNVs in Increasing the Diagnostic Yield of WES.’
MORE women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, research shows.
“EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period” in a Large Head-to-Head Breast Cancer Study
Cancer is a disease of abnormal gene function. Some gene changes that lead to cancer may be inherited. Breast, ovarian, prostate, and colon are some of these cancers that are linked to a family history. The genetic mutations that cause many of the known hereditary cancer syndromes have been identified, and genetic testing can confirm whether a condition is the result of an inherited syndrome. Genetic profiling may help you or other family members in planning health care for the future.
A companion diagnostic is a medical device which provides information that is essential for the safe and effective use of a corresponding drug. The test helps health care professionals identify patients who are most likely to benefit from a particular therapeutic product and patients who are likely to be at increased risk for serious side effects as a result of treatment. Companion diagnostics can also be used to monitor patient response to treatment for the purpose of adjusting treatment to achieve improved safety or effectiveness.
Nearly 1 in 5 individuals suffer from mental illness. There are over 270 medications containing warnings, precautions and dosage recommendations based on specific gene variants. Two thirds of patients will not achieve complete relief from their first medication.* Emerging science has allowed Genomind to develop a test designed to assist in the safe and appropriate selection of pharmacologic treatment for individuals who suffer from mental illness. Genomind’s leading mental health genetic test was designed to unlock unique insights for your clinician to more quickly identify a personalized treatment plan to help you avoid the painful process of treatment by trial and error *Depression Patients, Based on the STAR*D Trial
Rare genetic disorders can go undiagnosed for years. The lack of a diagnosis can have considerable adverse effects for patients and their families, including failure to identify potential treatments, failure to recognize risk of recurrence in subsequent pregnancies, and failure to provide anticipatory guidance and prognosis. Genetic testing has proven to be effective in detecting rare variants in an individual’s genome, offering hope to individuals with previously undiagnosed or untreated rare disorders.